Addressing current treatment challenges in Crohn's disease in real life: A physician's survey by Vavricka, Stephan R et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Addressing current treatment challenges in Crohn’s disease in real life: A
physician’s survey
Vavricka, Stephan R; Radivojevic, Sanja; Manser, Christine N; Frei, Pascal; Burri, Emanuel; Fried,
Michael; Schoepfer, Alain; Peyrin-Biroulet, Laurent; Michetti, Pierre; Rogler, Gerhard; Biedermann,
Luc
Abstract: BACKGROUND: In recent years several trials have addressed treatment challenges in Crohn’s
disease. Clinical trials however, represent a very special situation. AIMS: To perform a cross-sectional
survey among gastroenterologists on the current clinical real life therapeutic approach focussing on the
use of biologics. METHODS: A survey including six main questions on clinical management of loss of
response, diagnostic evaluation prior to major treatment changes, preference for anti-tumour necrosis
factor (TNF) agent, (de-)escalation strategies as well as a basic section regarding personal information
was sent by mail to all gastroenterologists in Switzerland (n=318). RESULTS: In total, 120 questionnaires
were analysed (response rate 37.7%). 90% of gastroenterologists in Switzerland use a thiopurine as the first
step-up strategy (anti-TNF alone 7.5%, combination 2.5%). To address loss of response, most physicians
prefer shortening the interval of anti-TNF administration followed by dose increase, switching the biologic
and adding a thiopurine. In case of prolonged remission on combination therapy, the thiopurine is stopped
first (52.6%) after a mean treatment duration of 15.7 months (biologic first in 41.4%). CONCLUSIONS:
Everyday clinical practice in Crohn’s disease patients appears to be incongruent with clinical data derived
from major trials. Studies investigating reasons underlying these discrepancies are of need to optimize
and harmonize treatment.
DOI: 10.1016/j.dld.2014.08.001
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-105041
Accepted Version
Originally published at:
Vavricka, Stephan R; Radivojevic, Sanja; Manser, Christine N; Frei, Pascal; Burri, Emanuel; Fried,
Michael; Schoepfer, Alain; Peyrin-Biroulet, Laurent; Michetti, Pierre; Rogler, Gerhard; Biedermann, Luc
(2014). Addressing current treatment challenges in Crohn’s disease in real life: A physician’s survey.
Digestive and Liver Disease, 46(12):1066-1071. DOI: 10.1016/j.dld.2014.08.001
Addressing current treatment challenges in Crohn’s disease in 
real life: a physician’s survey  
 
How are current treatment paradigms in Crohn’s disease patients with anti-TNF therapy 
addressed in real life? 
 
TNF inhibitors use for Crohn’s disease in Switzerland: a physician’s survey 
 
Stephan R. Vavricka1*, Sanja Radivojevic1*, Christine N. Manser2, Pascal Frei3, Emanuel 
Burri4, Alain Schoepfer5, Laurent Peyrin-Biroulet6, Gerhard Rogler2 and Luc Biedermann2 
 
 
 
1 Division of Gastroenterology & Hepatology, Triemli Hospital, Zurich, Switzerland.  
2 Gastroenterology & Hepatology, University Hospital Zurich, Zurich, Switzerland. 
3 Division of Gastroenterology & Hepatology, Seespital Horgen, Horgen, Switzerland. 
4 Division of Gastroenterology & Hepatology, Medical University Hospital Liestal, Liestal, Switzerland. 
5 Division of Gastroenterology & Hepatology, University Hospital Lausanne, Lausanne, Switzerland. 
6 Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy-Brabois, 
Vandoeuvre-lès-Nancy, France. 
 
*SRV and SR contributed equally to this work. 
 
Correspondence: Dr. Luc Biedermann, MD; Division of Gastroenterology and Hepatology, University Hospital 
Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. Phone: +41-(0)44-255-9334, Fax: +41-(0)44-255-9497, E-
mail: luc.biedermann@usz.ch 
  
Abstract 
Background 
In recent years several trials have addressed treatment-optimization, loss of response (LOR), 
preventing toxicity as well as over- and under-treatment with respect to immunosuppression and 
anti-TNF targeted therapy in Crohn’s disease (CD). While the evidence available has been 
summarized in respective guidelines several questions with respect to the optimal time point of 
treatment start, efficacy of combination therapy, optimization of dosing and safety remains to be 
answered. Most data have been derived from clinical trials which represent a very special situation. 
In contrast little is known about the current real life approach in clinical practice. Therefore, we 
performed a cross-sectional survey. 
 
Methods 
A questionnaire including six questions was sent by mail to all gastroenterologists in Switzerland 
(n=318). Responses were analyzed both as a total and stratified according to pre-specified subgroups 
(number of IBD patients seen and treated with anti-TNF per year, years in clinical practice and 
practice setting). 
 
Results 
A total of 120 physicians (37.7%) responded to the survey and could be analyzed. Ninety percent of 
gastroenterologists in Switzerland use a thiopurine as the first step up strategy, followed by anti-TNF 
alone (7.5%) or in combination therapy (2.5%). The most preferred TNF-antagonist is infliximab (IFX, 
47.1%) followed by adalimumab (ADA, 10.9%) and certolizumab pegol (CTZ, 0.8%), while 41.2% of all 
gastroenterologists have no specific preference for a TNF-antagonist. IFX is mainly preferred by 
gastroenterologists treating ≤ 10 patients per year with anti-TNF (57.6% vs. 35.2% for physicians 
treating > 10 patients per year; p=0.02). To address LOR most physicians prefer shortening the 
interval of anti-TNF administration followed by dose increase, switching the TNF-inhibitor and adding 
a thiopurine. In case of prolonged remission on combo therapy the thiopurine is stopped first in 
52.6% of cases after a mean treatment duration of 15.7 months (TNF-inhibitor stopped first in 41.4%; 
both therapies continued in 4.3%; both stopped at the same time in 1.7%). 
 
Conclusions 
Everyday clinical practice significantly differs from current CD treatment paradigms.  
  
Introduction 
The introduction of tumor-necrosis factor (TNF) inhibitors more than 10 years ago in the treatment 
of Crohn’s disease (CD) represents a major therapeutic breakthrough 1 . Since the first double-blind, 
placebo-controlled trial with Infliximab (IFX) 2 numerous pivotal trials on the efficacy of IFX, 
Adalimumab (ADA) and Certzolizumab pegol (CTZ) in inducing and maintaining clinical response and 
remission and achieving mucosal healing have been published 2–7. 
Since the early days, concerns regarding safety, above all opportunistic and severe infectious as well 
as neoplastic diseases have been raised 2,8. Even after extensive world-wide experience with anti-
TNF-therapy in IBD and other indications, such as rheumatological or dermatological diseases, there 
still is some uncertainty about potential risks 9–13. In the last few years, there has been an increasing 
trend towards an earlier introduction of TNF-inhibitors (which is associated with a better efficacy 14) 
either via a rapid step up 15,16 or top down 17, to avoid prolonged steroid exposure and minimizing CD-
associated morbidity and the need for surgery. 
Since the SONIC-trial 18 the initial use of anti-TNF in combination with a thiopurine has been 
advocated at least in patients with high-risk features for a disabling disease course and consecutively 
has also been included in therapeutic guidelines 19. 
Aside from treatment optimization de-escalation of therapy after variable duration of clinical 
remission and associated factors predicting success have been studied 20–22. However, attitude may 
differ between physicians and between countries. 
Also, the question of applying the best clinical strategy when confronted with loss of response (LOR) 
in patients receiving maintenance anti-TNF therapy has emerged. LOR occurs in a significant fraction 
of patients and has been reported to occur in about 20-50% of patients within the first year of 
therapy 5,23. Switching anti-TNF has been shown to be an effective strategy in case of LOR and drug 
intolerance 24–27 but should be omitted simply for the reason of a more convenient route of drug 
administration 28. Even after failure of two anti-TNF agents, there may be considerable rates of 
response and remission using a third one 29. Nonetheless, at this point in time only in the US and 
Switzerland such a third agent is available without a specific reimbursement application. 
The few studies having looked at adherence to guidelines among gastroenterologists have revealed 
equivocal results 30,31. However, the treatment of CD appeared to be appropriate in most patients 
according to cohort studies from Switzerland and Europe 32,33. 
Despite a multitude of published trials clinical real life differs – looking at a selection of pivotal IBD 
trials, less than a third of unselected real life IBD patients would have been actually suited for 
inclusion 34. We thus aimed to obtain a comprehensive overview on the clinical practice of GI 
specialists in Switzerland involved in the care of CD patients in the biologics era and gain insights on 
how these challenging treatment paradigms are currently addressed in a real-life setting. 
  
Material and Methods 
A questionnaire was sent to all Swiss gastroenterologist (n = 318) by conventional mail. This 
questionnaire had six questions addressing step-up and de-escalation strategies in the treatment of 
CD and preference for any specific TNF antagonist and included also a basic section regarding 
personal information of the respondent (Supplementary Figure 2). 
Responses were analyzed both in total as well as stratified according to the number of IBD patients 
seen and treated with anti-TNF per year, years in clinical practice and practice setting. Statistical 
Analyses were performed with SPSS (Version 21; IBM, Armonk, NY, USA) and Prism (Version 6, 
GraphPad Software, La Jolla, CA, USA). To investigate potential differences between the pre-specified 
subgroups Chi-Square testing was used. 
As far as the interval on prolonged remission prior to stopping one or both medical treatments 
D'Agostino & Pearson omnibus normality test was used, revealing a non-normal distribution. 
Consecutively Kruskal-Wallis test was used to evaluate whether there are any differences in mean 
values between the subgroups. Mann-Whitney test was then applied to directly compare between 
subgroups. 
  
Results 
 
Response rate and characteristics of responders 
Of the 318 Swiss gastroenterologists receiving our invitation to participate in the survey 120 (37.7%) 
responded and could be analyzed. The mean age of the responding GI specialists was 48.4 (± 9.8) 
years (89.1% male) with a mean professional experience as a gastroenterologist of 15.1 (±9.3) years. 
The majority of gastroenterologists provide clinical care in private practice or smaller hospitals, while 
only about a third of responders practice in university hospitals or large non-university hospitals 
(Table 1).  
 
Table 1 
Number of IBD patients 
seen (past year) 
1-30 31-100 >100  
61 
(50.8%) 
44 
(36.7%) 
15 
(12.5%) 
Number of IBD patients 
treated with anti-TNF  
(past year) 
1-10 11-30 31-100 >100  
66 
(55%) 
39 
(32.5%) 
12 
(10%) 
3 (2.5%) 
Practice setting* 
(Total) 
Private 
practice 
District 
hospital 
Private 
hospital 
Large 
non-
university 
hospital 
University 
hospital 
47 
(38.8%) 
26 
(21.7%) 
6.5 
(5.4%) 
17.5 
(14.6%) 
24 
(19.6%) 
 Practice 
setting* 
- per IBD 
patients 
seen 
1-30 19.5 
(32%) 
16.5 
(27%) 
3.5 
(5.7%) 
10.5 
(17.2%) 
11 (18%) 
31-100 22.5 
(51.1%) 
8.5 
(19.3%) 
3 (6.8%) 4 (9.1%) 6 (13.6%) 
>100 4.5 
(30%) 
1 (6.7%) 0 3 (20%) 6.5 
(43.3%) 
Practice 
setting* 
- per 
patients 
treated with 
anti-TNF 
1-10 28.5 
(43.2%) 
16.5 
(25%) 
3.5 
(5.3%) 
7.5 
(11.4%) 
10 
(15.2%) 
11-30 14.5 
(37.2%) 
8.5 
(21.8%) 
3(7.7%) 6 (15.4%) 7 (17.9%) 
31-100 2 
(16.7%) 
1 (8.3) 0 4 (33.3%) 5 (14.7%) 
>100 1.5 
(50%) 
0 0 0 1.5 (50%) 
 
 
Table 1.: Baseline characteristics of responding gastroenterologists. In the lower part of the table 
practice setting is further stratified by IBD patients seen or IBD patients treated with anti-TNF per 
year, respectively (*uneven numbers are due to the fact that regarding practice setting more than 
one affiliation could be stated). 
  
Preferred step up strategy? 
After lack of response to systemic steroids, budesonide, 5-aminosalicylates or an inability to taper 
these agents, the majority of Swiss gastroenterologists (90%) use a conventional step up strategy 
with thiopurine as a first-line therapy. Only 7.5% of responders use anti-TNF therapy alone , 2.5% use 
combination therapy (thiopurine combined with TNF-inhibitor) as a first-line therapy. We did not 
observe any statistical differences in the strategy with regard to any of the pre-specified subgroups 
(number of IBD patients seen and treated with anti-TNF per year, years in clinical practice and 
practice setting). Notably, there is not an increased primary use of anti-TNF (either as mono-therapy 
or in combination with thiopurine) in referral centers versus smaller hospitals or private practise 
(Supplementary Figure 1). 
Based on the data from the SONIC trial we calculated the efficacy of the treatment strategies 
according to the practicing physicians from our survey as well as the efficacy gap, assuming that in 
the comparison group all patients would have been receiving a combo-therapy in 1000 imaginary CD 
patients (Figure 1). 
 
 
Figure 1: Preferred step-up strategy. Efficacy of an imaginary 1000 CD patients treated with the 
conventional approach of gastroenterologist in our survey (percentage under the brace) in 
comparison to the same patients treated all with combination therapy (percentage aside grey bar) is 
shown, including the efficacy gap (percentage within purple bar), using the established efficacy data 
on several endpoints from SONIC. 
  
Preference for a specific TNF-inhibitor? 
Almost half (41.2%) of Swiss gastroenterologists have no preference for a specific anti-TNF agent. 
Among responders having a preference for a given anti-TNF, IFX is by far the preferred anti-TNF 
agent (47.1%), while 10.9% and 0.8% stated ADA and CTZ, respectively, to be their initial agent of 
choice (Figure 2). IFX is significantly more preferred in those physicians seeing less than 30 IBD 
patients per year (57.4% vs. > 30 Pat: 37.3%; p=0.03) and those treating less or equal than 10 
patients with anti-TNF per year (57.6% vs. >10 Pat: 35.2%; p=0.02). The preference according to the 
pre-specified subgroups is shown in Supplementary Figure 2. 
  
  
Figure 2 A, B, C: Preference for anti-TNF. The preferred agents in total (A) and per subgroups patients 
seen per year (B) and patients treated with anti-TNF per year (C) are depicted (significant differences 
between the subgroups are highlighted with asterisks; p=0.021 (B), p=0.015 (C)).  
  
A 
B 
C 
How to address loss of response? 
In case of LOR, the most preferred strategy is shortening the interval of anti-TNF administration.  
In the questionnaire two almost identical questions aimed at investigating the preferred treatment 
approaches when facing LOR. However, in the first question the preferred sequence of all given 
treatment strategies to address LOR had to be stated (from 1 to 7 for most preferred to least 
preferred, respectively), while in the second question responders were to rate all given strategies on 
a scale from 1 to 6 (with lowest and highest agreement, respectively). As regards the separate 
evaluation of every provided strategy (question II) Swiss gastroenterologists favor three options to 
optimize treatment by modifying the application of anti-TNF to a similar extent: shortening the 
interval (mean value of all answers from the scale from 1 to 6: 5.4), increasing by doubling the dose 
(5.0) and switching to another anti-TNF (4.9). Adding a thiopurine (3.9), initiating a full anti-TNF re-
induction (3.6), adding corticosteroids (3.5) or referring the patient to surgery (3.5) is considered 
inferior. Adding methotrexate (2.9) is not among the preferred strategies (Figure 3A).  
However, looking at the preferred sequence of all these given strategies to address LOR (question I) a 
clearer preference of shortening the interval becomes evident: this strategy is voted as best option 
by the vast majority of gastroenterologists (46.9%). Doubling the dose (20.4%) and switching the 
TNF-inhibitor (4.4%) are less often referred to as being the best approach. The latter receives even 
less approval as best option than starting a full re-induction of anti-TNF (5.3%) or adding prednisone 
(4.4%). 
We did not find any significant differences in the preference of the step-up strategy according to IBD 
patients seen or treated with anti-TNF per year, practice setting (hospital vs. general practice) as well 
as years of clinical experience.  
  
3A 
 
3B 
 
Figure 3 A, B: Preferred strategies to address LOR. Results of separate evaluation of any of the given 
strategies on a scale from 1-6 are depicted with error bars depicting standard deviation in Figure 3A. 
In Figure 3B results of sequential voting for any given option from 1 to 7 are shown. Dark bars show 
the percentage of any given option receiving vote as best option (1 in sequential voting), while 
brighter bars indicate percentage of any given option receiving a top 3 vote (1, 2 or 3 in sequential 
voting). In the few cases, where an individual approach was written by the respondent within the 
option “other”, the most stated answers were “investigate other causes of clinical deterioration”, 
above all “rule out infectious cause”, “discuss surgery” and “increase dose (but not double)”. 
  
Prolonged remission on combo therapy – how to de-escalate, and when? 
In case of prolonged remission on combination therapy the gastroenterologists stop the thiopurine 
first in most cases (52.6%). In contrast, 41.4% prefer to primarily stop the TNF-inhibitor. Only 4.3% 
continue both therapies indefinitely despite prolonged remission on combination therapy, while only 
1.7% of responders stop both medications at the same time (Figure 4 A). The mean interval on 
prolonged remission considered adequate for treatment de-escalation is 15.7 month, with a wide 
range from 6 to 48 month. 
As far as the interval of prolonged remission with combo-therapy considered sufficient, substantial 
heterogeneity is observed among physicians stopping either one or both drugs (Figure 4 B). There is 
no significant difference in the preference for a de-escalation treatment strategy in the pre-specified 
subgroups. However, the interval on combo-therapy considered sufficient prior to de-escalation is 
significantly longer in those physicians seeing less than 30 IBD patients per year (mean 17.5 vs. 13.5 
month, p = 0.017) and treating less than 10 IBD patients with anti-TNF, respectively (mean 17.4 vs. 
13.2 month, p < 0.01). In contrast, no significant differences regarding the interval are observed 
according to hospital setting or years in practice. However, with regard to the latter, there is a trend 
towards a shorter interval in physicians < 10 years in practice (14.4 vs. 17.4 years in those > 10 years 
of professional experience, p = 0.067). Of note, although not significant, physicians who de-escalate 
within a year after initiation of treatment by trend have a stronger preference to stop the 
immunosuppressant first, while this is more balanced in the group de-escalating after 1 year of 
combo-therapy with even a trend towards stopping the TNF-inhibitor first (p = 0.08).  
  
Figure 4. 
 
Figure 4 A 
 
 
Figure 4 B 
Figure 4: Treatment de-escalation. Vote for the different strategies of de-escalation are shown in 
Figure 4 A. The interval on remission in month (x-axis) considered adequate prior to de-escalation is 
shown according to physicians’ subgroups (mean values with standard error mean, SEM) is depicted 
in Figure 4 B.  
  
 Discussion 
We here report the results of a questionnaire including 6 sections regarding important treatment 
paradigms in CD. Despite first pivotal clinical trials addressing elements covered in this survey, a 
common ground of all contained issues is a lack of sufficient evidence to define the optimal clinical 
strategy at the present time. Yet, even if there was more evidence, the obvious differences of real-
life medicine and ideal world of clinical trials 34 raises concerns regarding general transferability for 
the clinician. Therefore, not only data on how specific treatment challenges in CD SHOULD be 
addressed based on clinical trials but also on how these challenges in fact ARE addressed in real life 
are essential to identify future needs and treatment gaps to set the stage towards an optimization in 
the treatment of IBD. 
The preference for an immunosuppressant as the first-line step-up-option is striking, with 9 out of 10 
Swiss gastroenterologist voting for this approach. However, this question did not contain any patient 
characteristics and one may speculate, that the answer would have differed substantially, if any 
indicators of a disabling disease course would have been given. Moreover, the answer does not allow 
drawing any conclusion, on when the treating physician would go for a next step in case of providing 
suboptimal clinical, biochemical or endoscopic response. The magnitude of the preference for a 
conventional step-up approach is nonetheless striking - especially considering the liberal 
reimbursement situation in Switzerland - and may appear somewhat “outdated”. However, using an 
immunosuppressant agent first with or without a corticosteroid is completely in line with major CD-
treatment recommendations and guidelines 15,19,35. This practice is not in contradiction to the 
increasing body of evidence, that anti-TNF based strategies are more effective in achieving crucial CD 
endpoints 18 and the recently published data on thiopurines, revealing no benefit of an early 
introduction regarding the primary endpoints 16,36. Although the top-down approach has been shown 
to be superior in inducing remission, reducing the need for steroids and achieving mucosal healing, 
there was no clinical benefit regarding long-term remission rates beyond 52 weeks between early 
combined immunosuppression (top-down) and conventional management (bottom-up) groups 17. 
Those physicians having more experience in the treatment of IBD patients clearly reveal to have less 
preference for a specific anti-TNF agent in general and for IFX in specific. Interestingly – in contrast to 
what one might assume based on the difference in the application mode between IFX and ADA/CTZ – 
the preference for the i.v. agent is even stronger in physicians in private practice compared to their 
colleagues in a hospital setting. This holds true despite the fact, that potential obstacles associated to 
IFX, such as the need for an infusion unit with monitoring for potential infusion reactions and fixed 
treatment schedules, evidently are more of an issue in private practice. 
Regarding the preferred treatment options to address LOR there apparently is somewhat a 
discrepancy between the answers for question I, where physicians were asked to provide their 
preferred sequence of all given options, and for question II, where each option was to rate 
independently. Sequencing the order of preferred options more clearly emerges the preference of 
shortening the interval. This choice is in line with current treatment recommendations to optimize 
treatment in LOR 37–40. However, the independent rating for every option given (question II) is 
indicative of an overuse of switching the TNF-inhibitor by GI specialist participating in this survey. 
Adding prednisone is among the least preferred strategies in question II (3.6). Nevertheless, adding 
prednisone is voted as the third best option in the sequential vote, being even the most preferred 
strategy in one out of six gastroenterologists (15.9%). This is remarkable, as adding corticosteroids in 
LOR has not been shown to be effective in this setting, thus it is not included in treatment 
recommendations 23. On the other hand, a watchful waiting approach in LOR patients with mild 
symptoms has been recommended 23,41, as the symptoms of LOR may be transient without any 
further change of clinical management. Thus, the short-term addition of steroids indeed may be 
considered an adequate symptomatic bridge. Adding a thiopurine clearly is not among the preferred 
strategies, chosen as fist option by only 3.5%. 
In case of prolonged remission only a notably small fraction of gastroenterologists prefer to continue 
both therapies for an indefinite period of time. The vast majority performs a de-escalation of medical 
treatment, which may be considered in line with the current evidence from the literature, despite a 
growing advocacy to “never stop combo-therapy” especially in North America 42. In one of the very 
few trials prospectively investigating treatment de-escalation in CD, patients received combination 
treatment for a minimum of one year with a minimum of 6 month of corticosteroid-free remission. 
Relapse risk was strongly related to the number of several specified risk factors present 20. However, 
in contrast to this trial the majority of gastroenterologists in our survey stop the immunosuppressive 
agent first, in line with another European study 21. Of note, those physicians seeing and treating more 
IBD patients per year consider a shorter interval being sufficient to initiate withdrawal of medical 
treatment. The wide range of this interval is in line with the current unequivocal body of evidence 
from the literature. The six month interval on the lower range is in line with the results from a 
Belgium withdrawal trial 21, whereas a longer interval (up to 4 years in our survey) is rather in line 
with a retrospective analysis 22, suggesting an increased risk of mono-therapy failure if the thiopurine 
is withdrawn after <27 month of combo-therapy. Currently, several questions regarding combination 
therapy remain unanswered, including sustained efficacy and risks beyond one year or adaptability of 
the conclusions drawn from SONIC to the subcutaneous TNF-antagonists (with the current literature 
available, the latter may be called into question 43,44). Thus, larger trials on different de-escalation 
strategies are an unmet need.  
 
As with all surveys, this study has several limitations. Results from a questionnaire have always to be 
interpreted with caution, as a genuine image of reality cannot necessarily be presumed: Answering a 
questionnaire is not equal to clinical practise. The response rate of 38% may appear low. However, 
the rate is in line respectively rather above the typical response rates from survey studies in 
physicians 45–48, known to be notoriously lower than in patient surveys 48. More importantly, we 
believe in accurate representativity of our sample: Our results do not reflect the current clinical 
procedural standard from a selection of clinical opinion leaders from IBD referral centers but were 
obtained to a high extent from gastroenterologist in private practice. Switzerland is an ideal country 
to obtain this empiric data, due to the small size of the country and the limited number of GI 
specialists in active clinical practice, allowing the acquisition of an image representative for the whole 
country.  
Moreover, in this country there is a substantial clinical experience with three anti-TNF agents 
registered for CD (apart from the US the only country in the world), including a relatively liberal 
reimbursement policy. The latter enables gastroenterologists in Switzerland to virtually always 
introduce anti-TNF in CD if considered clinically indicated which is why our results are not to be 
interpreted to be derived by substantial economic pressure.  
Unfortunately, based on this survey, we are not able to draw any conclusions regarding the 
underlying reasons for differences in the preference for a specific agent (such as higher and longer 
experience with infliximab including the amount of available data, subjective perception of different 
clinical effectiveness, desire to regularly follow the patient within the fixed infusion interval, or 
simply monetary considerations). 
 
To sum up, the vast majority of all Swiss GI specialists still apply a conventional step-up approach. 
Among those Swiss gastroenterologists having a specific preference for a TNF-inhibitor (58.2%), IFX is 
by far the most commonly stated agent. In case of LOR dose intensification prior to switching of the 
TNF-inhibitors is the most frequently used strategy. If prolonged remission has been achieved, 
stopping the immunosuppressant first is preferred. Although there is a large heterogeneity in what is 
considered an adequate interval of remission prior to de-escalation, those GI-specialist seeing more 
IBD patients and using more anti-TNF therapy are applying de-escalation within a significantly shorter 
interval of remission. In conclusion, we here present a comprehensive overview on the clinical 
practice of GI specialists in Switzerland regarding common and yet insufficiently resolved treatment 
paradigms in CD, aiming to capture the current pace of clinical reasoning and decision-making in the 
care of CD patients. Our results indicate that there is a discrepancy between real-life clinical practice 
and implications derived from recent pivotal studies, such as the SONIC-, STORI- or “Top Down-Trial”. 
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